Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 25;17(2):e0264703.
doi: 10.1371/journal.pone.0264703. eCollection 2022.

Progression of age-related macular degeneration in eyes with abnormal fundus autofluorescence in a Japanese population: JFAM study report 3

Affiliations

Progression of age-related macular degeneration in eyes with abnormal fundus autofluorescence in a Japanese population: JFAM study report 3

Yuji Oshima et al. PLoS One. .

Abstract

Purpose: To evaluate the progression of early age-related macular degeneration to neovascular age-related macular degeneration (nAMD), and identify the abnormal fundus autofluorescence (FAF) patterns and markers of choroidal neovascularization (CNV) in fellow eyes of patients with unilateral nAMD.

Methods: Sixty-six patients with unilateral nAMD who developed abnormal FAF in the fellow eyes were enrolled in this multicenter, prospective, observational study, and followed-up for 5 years. FAF images on Heidelberg Retina Angiogram Digital Angiography System (HRA) or HRA2 were classified into eight patterns based on the International Fundus Autofluorescence Classification Group system. The patients in which the fellow eyes progressed to advanced nAMD, including those who did not develop nAMD, were assessed based on the following factors: baseline FAF patterns, age, sex, visual acuity, drusen, retinal pigmentation, baseline retinal sensitivity, family history, smoking, supplement intake, hypertension, body mass index, and hematological parameters.

Results: Of the 66 patients, 20 dropped out of the study. Of the remaining 46 patients, 14 (30.42%, male: 9, female: 5) progressed to nAMD during the 5-year follow-up. The most common (50% eyes) FAF pattern in the fellow eyes was the patchy pattern. According to the univariate analysis, CNV development was significantly associated with age, supplement intake, and low-density lipoprotein levels (p<0.05). Multivariable analysis revealed that patients who showed non-compliance with the supplement intake were more likely to develop nAMD (p<0.05). No significant association was found between the patchy pattern and CNV development (p = 0.86).

Conclusion: The fellow eyes (with abnormal FAF) of patients with unilateral nAMD may progress from early to advanced nAMD. However, no FAF pattern was found that predicted progression in nAMD.

PubMed Disclaimer

Conflict of interest statement

Santen Pharmaceutical Co., Ltd. provided support in the form of honoraria for speaking and/or organizing at meetings [TY, RM, MS, AS, TS, Yuji Oshima, Yuichiro Ogura, TI, FG]. Mayumi Nakamura and Erika Kimura are employees of Santen Pharmaceutical Co., Ltd. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Figures

Fig 1
Fig 1. A representative case of retinal angiomatous proliferation.
A case of a 70-year-old woman that progressed to type 3 macular neovascularization (MNV). Fundus photograph (A) and fundus autofluorescence (FAF) image (B) at baseline. Confluent drusen (A) and patchy patterns of abnormal FAF (B) were confirmed. At the 6-month follow-up, the fellow eye progressed to type 3 MNV. Intraretinal bleeding, choroidal neovascularization, intraretinal and subretinal fluid, and pigment epithelial detachments were confirmed by fundus photography (C), fluorescein angiography (D), and optical coherence tomography (E).

References

    1. Swaroop A, Chew EY, Rickman CB, Abecasis GR. Unraveling a multifactorial late-onset disease: from genetic susceptibility to disease mechanisms for age-related macular degeneration. Annu Rev Genomics Hum Genet. 2009;10: 19–43. doi: 10.1146/annurev.genom.9.081307.164350 - DOI - PMC - PubMed
    1. Fine SL, Berger JW, Maguire MG, Ho AC. Age-related macular degeneration. N Engl J Med. Wood AJJ, editor. 2000;342: 483–492. doi: 10.1056/NEJM200002173420707 - DOI - PubMed
    1. Francis PJ, Klein ML. Update on the role of genetics in the onset of age-related macular degeneration. Clin Ophthalmol. 2011;5: 1127–1133. doi: 10.2147/OPTH.S11627 - DOI - PMC - PubMed
    1. (V. ISION) CT, VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group, Chakravarthy U, Adamis AP, Cunningham ET, Goldbaum M, Guyer DR, et al.. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology. 2006;113: 1508.e1–1508.25. doi: 10.1016/j.ophtha.2006.02.064 - DOI - PubMed
    1. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al.. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355: 1419–1431. doi: 10.1056/NEJMoa054481 - DOI - PubMed

Publication types

Substances